OATP1B1-MEDIATED HEPATIC UPTAKE OF SN-38, AN ACTIVE METABOLITE OF IRINOTECAN, AND ITS INHIBITION BY UREMIC TOXINS IN HUMANS

被引：0
|
作者：
Fujita, K. [1 ]
Sugiura, T. [2 ]
Okumura, H. [2 ]
Umeda, S. [2 ]
Nakamichi, N. [2 ]
Sasaki, Y. [1 ]
Kato, Y. [2 ]
机构：
[1] Saitama Med Univ, Hidaka, Japan
[2] Kanazawa Univ, Kanazawa, Ishikawa, Japan
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2013年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S32 / S32
页数：1
相关论文
共 50 条
  • [1] Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38
    Mariko Iwase
    Ken-ichi Fujita
    Yuki Nishimura
    Natsumi Seba
    Yusuke Masuo
    Hiroo Ishida
    Yukio Kato
    Yuji Kiuchi
    Cancer Chemotherapy and Pharmacology, 2019, 83 : 993 - 998
  • [2] Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38
    Iwase, Mariko
    Fujita, Ken-ichi
    Nishimura, Yuki
    Seba, Natsumi
    Masuo, Yusuke
    Ishida, Hiroo
    Kato, Yukio
    Kiuchi, Yuji
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 83 (05) : 993 - 998
  • [3] Cooperative inhibitory effects of uremic toxins and other serum components on OATP1B1-mediated transport of SN-38
    Katsube, Yurie
    Tsujimoto, Masayuki
    Koide, Hiroyoshi
    Ochiai, Megumi
    Hojyo, Ayako
    Ogawa, Kaori
    Kambara, Kengo
    Torii, Nao
    Shima, Daisuke
    Furukubo, Taku
    Izumi, Satoshi
    Yamakawa, Tomoyuki
    Minegaki, Tetsuya
    Nishiguchi, Kohshi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (04) : 783 - 789
  • [4] Cooperative inhibitory effects of uremic toxins and other serum components on OATP1B1-mediated transport of SN-38
    Yurie Katsube
    Masayuki Tsujimoto
    Hiroyoshi Koide
    Megumi Ochiai
    Ayako Hojyo
    Kaori Ogawa
    Kengo Kambara
    Nao Torii
    Daisuke Shima
    Taku Furukubo
    Satoshi Izumi
    Tomoyuki Yamakawa
    Tetsuya Minegaki
    Kohshi Nishiguchi
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 783 - 789
  • [5] Direct Inhibition and Down-regulation by Uremic Plasma Components of Hepatic Uptake Transporter for SN-38, an Active Metabolite of Irinotecan, in Humans
    Fujita, Ken-ichi
    Sugiura, Tomoko
    Okumura, Hidenori
    Umeda, Saki
    Nakamichi, Noritaka
    Watanabe, Yusuke
    Suzuki, Hiromichi
    Sunakawa, Yu
    Shimada, Ken
    Kawara, Kaori
    Sasaki, Yasutsuna
    Kato, Yukio
    PHARMACEUTICAL RESEARCH, 2014, 31 (01) : 204 - 215
  • [6] Direct Inhibition and Down-regulation by Uremic Plasma Components of Hepatic Uptake Transporter for SN-38, an Active Metabolite of Irinotecan, in Humans
    Ken-ichi Fujita
    Tomoko Sugiura
    Hidenori Okumura
    Saki Umeda
    Noritaka Nakamichi
    Yusuke Watanabe
    Hiromichi Suzuki
    Yu Sunakawa
    Ken Shimada
    Kaori Kawara
    Yasutsuna Sasaki
    Yukio Kato
    Pharmaceutical Research, 2014, 31 : 204 - 215
  • [7] CHARACTERIZATION OF HEPATIC UPTAKE MECHANISM FOR SN-38, AN ACTIVE METABOLITE OF THE ANTICANCER AGENT IRINOTECAN IN HUMANS
    Kato, Yukio
    DRUG METABOLISM REVIEWS, 2012, 44 : 95 - 96
  • [8] Inhibition of OATP1B1-mediated uptake by macrolides
    Seithel, A
    Mürdter, T
    Fromm, MF
    König, J
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2006, 372 : 137 - 137
  • [9] POSSIBLE INVOLVEMENT OF OATP2B1 IN GASTROINTESTINAL TOXICITY INDUCED BY SN-38, THE ACTIVE METABOLITE OF ANTICANCER IRINOTECAN
    Fujita, Daichi
    Saito, Yoshimasa
    Nakanishi, Takeo
    Tamai, Ikumi
    DRUG METABOLISM REVIEWS, 2015, 47 : 287 - 288
  • [10] Development of ELISAs for irinotecan and its active metabolite SN-38
    Saita, T
    Fujito, H
    Mori, M
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2000, 23 (08) : 911 - 916
12345